These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20736989)

  • 1. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
    Furey ML; Khanna A; Hoffman EM; Drevets WC
    Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
    Ellis JS; Zarate CA; Luckenbaugh DA; Furey ML
    J Affect Disord; 2014 Jun; 162():39-42. PubMed ID: 24767003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
    Drevets WC; Furey ML
    Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline mood-state measures as predictors of antidepressant response to scopolamine.
    Furey ML; Nugent AC; Speer AM; Luckenbaugh DA; Hoffman EM; Frankel E; Drevets WC; Zarate CA
    Psychiatry Res; 2012 Mar; 196(1):62-7. PubMed ID: 22349648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
    Guo W; Machado-Vieira R; Mathew S; Murrough JW; Charney DS; Grunebaum M; Oquendo MA; Kadriu B; Akula N; Henter I; Yuan P; Merikangas K; Drevets W; Furey M; Mann JJ; McMahon FJ; Zarate CA; Shugart YY
    Transl Psychiatry; 2018 Dec; 8(1):280. PubMed ID: 30552317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder.
    Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD
    J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261
    [No Abstract]   [Full Text] [Related]  

  • 14. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
    Khan A; Khan SR; Shankles EB; Polissar NL
    Int Clin Psychopharmacol; 2002 Nov; 17(6):281-5. PubMed ID: 12409681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment.
    Pope HG; Amiaz R; Brennan BP; Orr G; Weiser M; Kelly JF; Kanayama G; Siegel A; Hudson JI; Seidman SN
    J Clin Psychopharmacol; 2010 Apr; 30(2):126-34. PubMed ID: 20520285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.
    Furey ML; Drevets WC; Hoffman EM; Frankel E; Speer AM; Zarate CA
    JAMA Psychiatry; 2013 Mar; 70(3):280-90. PubMed ID: 23364679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
    Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
    Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.